/IRWD

Ironwood Pharmaceuticals Inc

IRWD

$4.08USD↑+2.77%+0.11 today

MARKET CAP

674.2M

P/E (TTM)

5.1x

FWD P/E

3.1x

DAY RANGE

$4 – $4

52W RANGE

$1

$6

AI Summary

Stalk

StalkMedium

IRWD remains in a Stage 2 advancing context with price consolidating near the rising 200-day SMA. Medium-term bias stays bullish, but short-term momentum is negative as price trades below the 9/20-day EMA cluster. Execution is deferred: stalk long on pullbacks into the 9/20 EMA zone (~4.15–4.18) or holds at the 200-day SMA (~3.95). The long-term uptrend on the rising 200-day SMA remains intact; a sustained break below that level would invalidate the bullish view.

↑Q2 revenue $113M up 33% YoY, driven by Linzess’s 14% sales jump to $282.3M.
↑Full-year Linzess net sales guidance raised to $1.15–$1.20B on mid-single-digit demand growth.
↓Revenue tied almost exclusively to Linzess, exposing cash flow to demand swings.

Full analysis →

Buying

3

institutions

Selling

5

institutions

New Positions

0

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUY	17.79 M	74.89 M	+4.43 M	+59.7%	0.00%
RT Renaissance Technologies LLC Q2 2026	SELL	7.99 M	33.65 M	+-67.85 K	+18.9%	0.05%
AC Aqr Capital Management LLC Q2 2026	SELL	6.47 M	27.22 M	+-1.07 M	+2.9%	0.01%
CA Citadel Advisors LLC Q2 2026	BUY	676.70 K	2.85 M	+361.13 K	+157.2%	0.00%
MG Man Group Plc Q2 2026	SELL	392.12 K	1.65 M	+-148.75 K	-13.0%	0.00%
JC Jpmorgan Chase & Co Q2 2026	BUY	212.57 K	914.07 K	+94.38 K	+139.4%	0.00%
MM Millennium Management LLC Q2 2026	SELL	0.00	0.00	+-457.11 K	-100.0%	0.00%
BH Brevan Howard Capital Management LP Q2 2026	SELL	0.00	0.00	+-14.22 K	-100.0%	0.00%